NCT03480971: An ongoing trial by Matrix Biomed, Inc.
This trial is ongoing. It must report results 7 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03480971 |
|---|---|
| Title | A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 13, 2019 |
| Completion date | July 31, 2025 |
| Required reporting date | July 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |